{
    "clinical_study": {
        "@rank": "3351", 
        "arm_group": [
            {
                "arm_group_label": "rhTPO, 300Units/kg ,daily for 14 consecutive days", 
                "arm_group_type": "Experimental", 
                "description": "10 enrolled patients  randomly  receive rhTPO at a dose of 300Units/kg ,daily for 14 consecutive days"
            }, 
            {
                "arm_group_label": "rhTPO, 300Units/kg ,one times every other day for 7 times", 
                "arm_group_type": "Experimental", 
                "description": "10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,one times every other day for 7 times."
            }, 
            {
                "arm_group_label": "rhTPO, 300Units/kg ,daily for 7 consecutive days", 
                "arm_group_type": "Experimental", 
                "description": "10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,daily for 7consecutive days."
            }
        ], 
        "brief_summary": {
            "textblock": "The project was undertaking by Qilu Hospital of Shandong University and other well-known\n      hospitals in China. In order to study the efficacy and safety of different dose and\n      frequency Recombinant Human thrombopoietin in treating  the primary immune thrombocytopenia\n      (ITP)"
        }, 
        "brief_title": "A Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) With Different Frequencies in the Management of ITP", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Immune Thrombocytopenia", 
        "condition_browse": {
            "mesh_term": "Thrombocytopenia"
        }, 
        "detailed_description": {
            "textblock": "The investigators are undertaking a parallel group, multicentre, randomised controlled trial\n      of 30 primary ITP adult patients from 3 medical centers in China.  They will be randomly\n      assigned in a 1:1:1 ratio into three groups .The patients in  group A (total 10 patients)\n      will receive rhTPO at a dose of 300Units/kg ,daily for 14 consecutive days;The patients in\n      group B will  receive rhTPO  at a dose of 300Units/kg ,one times every other day for 7\n      times.The patients in group C will receive rhTPO  at a dose of 300Units/kg ,daily for 7\n      consecutive days .All the patients will follow with a flexible dosage depending on platelet\n      count during the following 12 weeks.\n\n      Platelet counts, bleeding and other symptoms were evaluated before and after treatment, in\n      order to evaluate the efficacy and safety of different dose and frequency Recombinant Human\n      thrombopoietin in treating  the primary immune thrombocytopenia (ITP)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject is \u226518 years old, may be male or female.\n\n          2. Diagnosed with ITP meeting the diagnostic criteria for immune thrombocytopenia.\n\n          3. Patients who have no response or relapsed after Corticosteroid.\n\n          4. To show a platelet count < 30\u00d710^9/L, and with bleeding manifestations.\n\n          5. Willing and able to sign written informed consent.\n\n        Exclusion Criteria:\n\n          1. Received chemotherapy or anticoagulants or other drugs affecting the platelet counts\n             within 3 months before the screening visit.\n\n          2. Received second-line ITP-specific treatments (eg, cyclophosphamide, 6-mercaptopurine,\n             vincristine, vinblastine, etc) within 3 months before the screening visit.\n\n          3. Received high-dose steroids or IVIG in the 3 weeks prior to the start of the study.\n\n          4. Current HIV infection or hepatitis B virus or hepatitis C virus infections.\n\n          5. Severe medical condition (lung, hepatic or renal disorder) other than chronic ITP.\n             Unstable or uncontrolled disease or condition related to or impacting cardiac\n             function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension\n             or cardiac arrhythmia)\n\n          6. Female patients who are nursing or pregnant, who may be pregnant, or who contemplate\n             pregnancy during the study period.\n\n          7. Have a known diagnosis of other autoimmune diseases, established in the medical\n             history and laboratory findings with positive results for the determination of\n             antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct\n             Coombs test.\n\n          8. Patients who are deemed unsuitable for the study by the investigator ."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02139501", 
            "org_study_id": "ITP-Thrombopoietin"
        }, 
        "intervention": {
            "arm_group_label": [
                "rhTPO, 300Units/kg ,daily for 14 consecutive days", 
                "rhTPO, 300Units/kg ,one times every other day for 7 times", 
                "rhTPO, 300Units/kg ,daily for 7 consecutive days"
            ], 
            "description": "rhTPO was given intravenously at a dose of300Units/kg ,daily for 14 consecutive days;at a dose of 300Units/kg ,one times every other day for 7 times; or at a dose of 300Units/kg ,daily for 7 consecutive days", 
            "intervention_name": "Recombinant Human Thrombopoietin (rhTPO)", 
            "intervention_type": "Drug", 
            "other_name": [
                "tpiao", 
                "Recombinant Human Thrombopoietin", 
                "Recombinant Human TPO"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Recombinant Human Thrombopoietin", 
            "Dose and frequency", 
            "Immune Thrombocytopenia"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Jinan", 
                    "country": "China", 
                    "state": "Shandong", 
                    "zip": "250012"
                }, 
                "name": "Qilu Hospital, Shandong University"
            }, 
            "investigator": {
                "last_name": "Ming Hou, Dr", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multi-center, Randomized Study to Evaluate the Efficacy and Safety of Different Doses and Frequencies of Recombinant Human Thrombopoietin (rhTPO) in the Management of Primary Immune Thrombocytopenia (ITP)", 
        "overall_contact": {
            "email": "houming@medmail.com.cn", 
            "last_name": "Ming Hou, Dr", 
            "phone": "+86-531-82169114", 
            "phone_ext": "9879"
        }, 
        "overall_official": {
            "affiliation": "Shandong University", 
            "last_name": "Ming Hou, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "response rate (CR+R) at the 14th day and the 14th week  from the initial injection of rhTPO. CR is defined as platelet count \u2265 100\u00d710^9/L, and R is defined as platelet count of >30 \u00d7 10^9/L with a least a doubling of the baseline value.", 
            "measure": "Early Response", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02139501"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shandong University", 
            "investigator_full_name": "Ming Hou", 
            "investigator_title": "Professor and Director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The type and frequency of therapy associated adverse events", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "1 years"
        }, 
        "source": "Shandong University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "The First Affiliated Hospital of Dalian Medical University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shandong Provincial Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Shandong University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}